



JFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-479-E)

In the Application of:	)	
	)	
Luiz Belardinelli et al.	)	
	)	Art Unit: 3737
Serial No.: 10/766,403	)	
	)	
Confirmation No. 3369	)	Examiner: Not Assigned
	)	
Filed: January 27, 2004	)	
	)	
Title: Myocardial Perfusion Imaging Methods	)	
And Composition	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97-1.98, applicants wish to make the following references of record in the above-identified application. These references may be material to the Examiner's consideration of the presently pending claims. Copies of the non-U.S. Patent references cited below are enclosed along with a completed Form-1449.

**U.S. Patents**

	<u>Patent No.</u>	<u>Inventors</u>	<u>Issue Date</u>
1.	4,956,345	Miyasaka et al.	September 11, 1990
2.	4,968,697	Hutchison	November 6, 1990

McDONNELL BOEHNNEN HULBERT & BERGHOFF LLP  
300 South Wacker Drive  
Chicago, Illinois 60606



PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-479-E)

In the Application of:	)	
	)	
Belardinelli	)	Art Unit: 3737
	)	
Serial No. 10/766,403	)	
	)	
Filed: January 27, 2004	)	Examiner: Not Assigned
	)	
Title: Myocardial Perfusion Imaging Method And Composition	)	

Commissioner for Patents  
P.O. Box 1450  
Arlington, Virginia 22313-1450


**TRANSMITTAL LETTER**

Sir:

In regard to the above identified application:

1. We are transmitting herewith the attached:
  - a. Information Disclosure Statement
  - b. Form PTO-1449
  - c. Cited Non U.S. Patent References
  - d. Return Receipt Postcard
2. With respect to additional fees:
  - a. Attached is a check in the amount of \$ -0-
3. Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 26th day of August, 2004.

Respectfully submitted,

By :   
A. Blair Hughes  
Reg. No. 32,901

	<u>Patent No.</u>	<u>Inventors</u>	<u>Issue Date</u>
3.	5,070,877	Mohiuddin et al.	December 10, 1991
4.	5,189,027	Miyashita et al.	February 23, 1993
5.	5,270,304	Kogi et al.	December 14, 1993
6.	5,459,254	Yamaguchi et al.	October 17, 1995
7.	5,593,975	Cristalli	January 14, 1997
8.	5,705,491	Yamada	January 6, 1998
9.	5,770,716	Khan et al.	June 23, 1998
10.	5,939,543	Morozumi et al.	August 17, 1999
11.	6,026,317	Verani	February 15, 2000
12.	6,214,807	Zablocki et al.	April 10, 2001
13.	6,403,567	Zablocki	June 11, 2002
14.	US2004/0127533	Hart et al.	July 1, 2004

#### **Foreign Patents**

	<u>Patent No.</u>	<u>Inventors</u>	<u>Publication Date</u>
1.	WO 93/25677	Pierce	December 23, 1993
2.	WO 00/78779	Zablocki et al.	December 28, 2000
3.	WO 00/78778	Zablocki et al.	December 28, 2000
4.	WO 01/62979	Belardinelli et al.	August 30, 2001
5.	WO 04/011010	Belardinelli et al.	February 5, 2004
6.	EP 0 354 638	Mohiuddin et al.	February 14, 1990

	<u>Patent No.</u>	<u>Inventors</u>	<u>Publication Date</u>
7.	965,411 (Canada)	Marumoto et al.	April 1, 1975
8.	Hei 5[1993]-9197 (Japan)	Matusudo et al.	January 19, 1993

### Other

1. Iskandrian, A, "Adenosine Myocardial Perfusion Imaging", *The Journal of Nuclear Medicine*, vol. 35, pp. 734-736 (1994).
2. Gao, et al., "Novel Short-Acting A<sub>2A</sub> Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A<sub>2A</sub> Agonists", *Journal of Pharmacology and Experimental Therapeutics*, vol. 298, pp. 209-218 (2001).
3. Marumoto, et al., "Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines", *Chem.. Pharm. Bull.* 23(4): 759-774 (1975).
4. Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", *Chem.. Pharm. Bull.* 27(4) 990-1003 (1979).
5. Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", *Bioorganic & Medicinal Chemistry*, 3:1377-1382 (1995).
6. Mager, et al., "Molecular simulation applied to 2-(N'alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A<sub>2</sub> Agonists", *Eur J. Med. Chem.* 30:15-25 (1995).
7. Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'ethyluronamide: Selective A<sub>2</sub> Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", *J. Med. Chem.* 37:1720-1726 (1994).
8. Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A<sub>2</sub> Receptor Agonists with Potent Antihypertensive Effects", *J. Med. Chem.* 35:241-252 (1992).


9. Xu, et al. "Coronary Vasodilation by a Short Acting, Low Affinity A2A Adenosine Receptor Agonist in Anesthetized Closed Chest Dogs: A Second Generation of Coronary Artery Pharmacologic Stressor", *Circulation*, vol. 102, no. 18, pp. 3912 (2000).

Respectfully submitted,

**McDonnell Boehnen  
Hulbert & Berghoff LLP**

Dated: August 26, 2004

By:

  
A. Blair Hughes  
Reg. No. 32,901